


PHARMACEUTICAL 2022

Evoke Pharma Inc Rank 376 of 475







PHARMACEUTICAL 2022

Evoke Pharma Inc Rank 376 of 475



The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Evoke Pharma Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 277% points.

The company's Economic Capital Ratio, given in the ranking table, is -350%, being 73% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	10,561
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,406
Liabilities, Non-Current	5,612
Other Assets	12
Other Compr. Net Income	0
Other Expenses	328
Other Liabilities	0
Other Net Income	-386
Property and Equipment	0
Research and Development	590
Revenues	1,618
Selling, General and Administrative Expense	8,851

Output Variable	Value in 1000 USD
Assets	10,573
Liabilities	7,018
Expenses	9,770
Stockholders Equity	3,555
Net Income	-8,538
Comprehensive Net Income	-8,538
Economic Capital Ratio	-350%

